Clinical Trials Directory

Trials / Terminated

TerminatedNCT02236546

FDG-PET in Advanced Melanoma

FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.

Detailed description

PRIMARY OBJECTIVES: I. To correlate treatment-induced changes in FDG uptake with changes in tumor size and progression-free survival (PFS) in patients receiving therapy for advanced melanoma. II. To correlate treatment-induced changes in FDG uptake with changes in the activity and/or expression of available molecular biomarkers from patients receiving therapy for advanced melanoma. OUTLINE: Patients undergo FDG-PET/CT up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST[18F]fluorodeoxyglucoseFDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
OTHERMolecular assays on biopsied tissueCorrelative studies
DEVICEpositron emission tomographyUndergo FDG-PET/CT
DEVICEcomputed tomographyCT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.

Timeline

Start date
2012-05-01
Primary completion
2014-10-01
Completion
2015-11-01
First posted
2014-09-10
Last updated
2017-04-13
Results posted
2017-04-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02236546. Inclusion in this directory is not an endorsement.